Abstract: Endothelial progenitor cells (EPCs), a CXCR4-bearing cell line, are thought to positively influence reendothelialization, vascular repair, and angiogenesis. AMD3100, a highly selective antagonist of stromal cell derived factor (SDF)-1 that binds to its receptor, CXCR4, has been shown to induce rapid mobilization of hematopoietic stem cells in mice, dogs, and humans. Results of this study indicate that AMD3100 injection can induce a rapid and potent mobilization of EPCs in mice compared with saline injection. The study demonstrates that murine spleen-derived EPCs can produce high levels of SDF-1 in vitro. Blocking this endogenous SDF-1 with AMD3100 decreases the number of EPCs; inhibits the proliferation, migration, and adhesion of EPCs; and induces EPC apoptosis. In addition, AMD3100 inhibits ectogenous SDF-1a induced improvement of EPC functions. However, AMD3100 incubation does not change the functions of CXCR4-negative cell line HPDE6. In conclusion, AMD3100 can be regarded as a potent mobilizer of EPCs in mice. EPCs have an autocrine/paracrine SDF-1 loop, and breaking this loop with AMD3100 can inhibit the EPC functions in vitro.
E ndothelial progenitor cells (EPCs) may be defined as adherent cells derived from peripheral blood-or bone marrow-derived mononuclear cells demonstrating acetylated low-density lipoprotein (ac-LDL) uptake and isolectin-binding capacity. 1 The number of circulating EPCs inversely correlates with the number of cardiovascular risk factors 1, 2 and is reduced in cardiovascular disease. 3 Moreover, several studies have demonstrated that patients with coronary heart disease or severe heart failure may suffer from impaired function of peripheral circulating EPCs. [2] [3] [4] Circulating, bone marrowderived EPCs may home into sites of neovascularization 5, 6 and participated in reendothelialization after vascular injury, [7] [8] [9] and differentiate into mature endothelial cells in situ. First clinical trials have been performed investigating the effects of EPC transplantation into cardiac ischemic areas after myocardial infarction, 10 in patients with peripheral atherovascular disease, 11 and on endothelialization of artificial heart valves. 12 Next to EPC transplantation, the pharmacological mobilization and functional modification of EPCs may also play a major role in future therapies.
Chemokine stromal cell derived factor-1 (SDF-1, also known as CXCL12) is constitutively produced by bone marrow stromal cells and by other cells including EPCs. 13 It was believed to be involved in homing of hematopoietic stem/progenitor cells into bone marrow and mobilization of hematopoietic stem/progenitor cells into peripheral blood. Recently, emerging evidence suggests that SDF-1 increases EPCs number through enhancement of (BM) c-kit + stem cell adhesion onto extracellular matrix components by integrin receptors 14 and protects EPCs from serum starvation-induced apoptosis. 15 Increasing the level of SDF-1 in peripheral blood has been shown to mobilize bone marrow-derived EPCs into perepheral blood. 14, 16, 17 Upregulated SDF-1 expression in ischemic tissues could also mobilize bone marrow-derived EPCs into peripheral blood and mediate them home to the site of neovascularization in ischemic tissues.
14,16 AMD3100, a highly selective antagonist of SDF-1 that binds to its receptor, CXCR4, has been shown to induce rapid mobilization of hematopoietic stem cells in mice, 18 dogs, 19 and humans, 18, 20 offering an alternative to granulocyte colony-stimulating factor (G-CSF) mobilization of these cells. However, the role of AMD3100 in mobilization of EPCs has not been established definitively. Given that EPCs can produce SDF-1 and express SDF-1 receptor CXCR4, 15 we raise a hypothesis that EPCs have an autocrine/paracrine SDF-1 loop that is involved in regulation of EPC functions, and breaking this loop with AMD3100 can affect EPC functions.
METHODS

Mobilization of EPCs
Male, 8-week-old C57BL/6 mice were purchased from the Center of Animals, Da Ping Hospital of The Third Military Medical University, Chongqing, China. All animal studies were approved by the Animal Research Committee of The Third Military Medical University and were done according to the guidelines of National Institutes of Health. To test time course of mobilization in response to a single subcutaneous (s.c.) injection of 5 mg/kg AMD3100 (Sigma) in C57BL/6 mice, peripheral blood murine samples were collected at different time points (0, 0.5, 1, and 6 hours) after injection of AMD3100 or sterile pyrogen-free saline. Dose-response analysis of AMD3100 at 1 hour after s.c. injection of 0.625, 1.25, 2.5, 5.0, or 10.0 mg/kg AMD3100 in C57BL/6 mice was also performed. For fluorescence-activated cell sorter analysis, the viable lymphocyte population in peripheral whole blood was analyzed for the expression of Sca-1-PE (eBiosciences) and VEGFR-2-FITC (eBiosciences). 21 Single-and two-color flow cytometric analyses were performed using a FACScan flow cytometer and Cell Quest software (BD Biosciences).
Cell Cultures and Incubation
Spleen-derived EPCs were cultured according to previously described techniques. 9 After 4 days in culture, cells were extensively washed with normal saline. Adherent cells were incubated with 2.4 mg/mL 1,1#-dioctadecyl-3,3,3#,3#-tetramethylindocarbocyanine-labeled acetylated LDL (DiLDL; Harbor Bio-Products) for 1 hour, fixed with 2% paraformaldehyde, and counterstained with fluorescein isothiocyanatelabeled lectin (Sigma). The numbers of DiLDL-and lectinpositive cells were evaluated by two independent investigators. Adherent cells were detached with 0.25% trypsin followed by repeated gentle flushing through a pipette tip and washed in phosphate-buffered saline (PBS). Cells were incubated with the following monoclonal antibodies: anti-Sca-1-PE (eBiosciences) and anti-VEGFR-2-FITC (eBiosciences), as well as their corresponding isotype controls. Flow cytometric analyses were performed using a FACScan flow cytometer and Cell Quest software (BD Biosciences).
The epithelial cell line derived from normal human pancreatic ducts HPDE6, kindly obtained from Dr. Xiao-Tong Shu (The Third Military Medical University, Chongqing, China), has been previously reported to have no expression of CXCR4.
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AMD3100 was dissolved and further diluted with endothelial basal medium (EBM) or Dulbecco/Vogt modified Eagle's minimal essential medium (DMEM) to make a series of final concentrations: 1, 5, 10, 50, or 100 ng/mL. AMD3100 in EBM was used to incubate EPCs. AMD3100 in DMEM was used to incubate HPDE6.
EPC Numbers In Vitro
Spleen-derived mononuclear cells (MNCs) were cultured for 2 days; cells were incubated with various AMD3100 concentrations for 24 hours or with 50 ng/mL AMD3100 for 6, 12, 24, and 48 hours. Cells also were incubated in EBM with 100 ng/mL SDF-1a, Sigma, or EBM with 50 ng/mL AMD3100 and 100 ng/mL SDF-1a for 24 hours. Nonadherent cells were removed by washing with PBS. Adherent cells were stained as above and cells double positive for DiLDL and lectin staining were judged as EPCs and counted (three random microscopic fields per well, 3400).
Proliferation Assay
EPCs were harvested and incubated with various AMD3100 concentrations for 24 hours. Then EPCs were supplemented with 10 mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (5 mg/mL) and incubated for a further 6 hours. The supernatant was discarded by aspiration and 200 mL of dimethyl sulfoxide was added to the EPC preparation and shaken for 10 min. The A value was measured at 490 nm. 23 To determine reaction time course, EPCs were treated with 50 ng/mL AMD3100 for 6, 12, 24, and 48 hours. EPCs were also incubated in EBM with 100 ng/mL SDF-1a or EBM with 50 ng/mL AMD3100 and 100 ng/mL SDF-1a for 24 hours. HPDE6 was incubated with various AMD3100 concentrations for 24 hours. Proliferation was measured according to above described techniques.
Migration Assay
EPCs were incubated with various AMD3100 concentrations for 2 hours. Cells migration was evaluated by using a modified Boyden chamber assay. 1 In brief, incubated EPCs of 2 3 10 4 were placed in the upper chamber of a modified Boyden chamber. Then 100 ng/mL SDF-1a in EBM was placed in the lower compartment of the chamber. After 24 hours incubation at 37°C, the lower side of the filter was washed with PBS and fixed with 2% paraformaldehyde. For quantification, cells were stained with Giemsa solution. Cells migrating into the lower chamber were counted manually in three random microscopic fields (3400). EPCs were also treated with 50 ng/mL AMD3100 for 0.5, 1, 2, and 4 hours. HPDE6 was incubated with various AMD3100 concentrations for 2 hours. Cells migration was evaluated as described above.
Cell Adhesion Assay
EPCs were incubated with various AMD3100 concentrations for 12 h or with 50 ng/mL AMD3100 for 3, 6, 12, and 24 hours. EPCs were also incubated with 100 ng/mL SDF-1a or with 50 ng/mL AMD3100 and 100 ng/mL SDF-1a for 12 hours. Cells were detached as described above. After centrifugation and resuspension in EBM/5% (v/v) fetal calf serum, identical cells were replated onto fibronectin-coated culture dishes and incubated for 30 min at 37°C. Adherent cells were counted in three random microscopic fields (3400). 7 
Apoptosis Assay
EPCs were incubated with various AMD3100 concentrations for 48 hours. Cells were then fixed with 2% paraformaldehyde for 10 min and washed 3 times with PBS. EPCs were permeabilized with 0.2% Triton-X and incubated in terminal deoxynucleotidyl transferase mediated dUTP nick end labeling assay (TUNEL) reaction mixture using the In Situ Cell Death Detection Kit (Boster) according to the manufacturer's recommended protocol. The number of TUNELpositive nuclei was regarded as EPC apoptosis, and the apoptosis percentage was calculated (three random microscopic fields, 3400). 24 EPCs were treated with 50 ng/mL AMD3100 for 6, 12, 24, 48, and 72 hours to detect apoptotic time course. Moreover, EPCs were incubated with 100 ng/mL SDF-1a or with 50 ng/mL AMD3100 and 100 ng/mL SDF-1a for 48 hours. HPDE6 was incubated with various AMD3100 concentrations for 48 hours. Apoptosis was determined.
Enzyme-Linked Immunosorbent Assay Test of SDF-1 in Cell Culture Supernatants
Spleen-derived EPCs were cultured according to previously reported techniques. 9 After 4 days in culture, nonadherent cells were removed by washing with PBS and fresh media was added. The media was then changed every 3 days and the culture was maintained until 13 days. The media of different culture time span (days 1 to 4, days 4 to 7, days 7 to 10, days 10 to 13) was obtained and centrifuged. SDF-1a determination was performed by SDF-1a enzyme-linked immunosorbent assay kit (MCX120; R&D Systems) according to the manufacturer's instructions using 100 mL undiluted cell culture supernatants or unused media samples. 25 
Statistical Analysis
All data are presented as means 6 SD. Differences between group means were assessed by an independentsample t test for single comparisons and by analysis of variance for multiple comparisons. P , 0.05 was considered significant.
RESULTS
AMD3100 Mobilized Murine EPCs
In the present study, the effects of AMD3100 on mobilization of EPCs to the peripheral blood of C57BL/6 mice were evaluated. Using a dose of 5 mg/kg AMD3100 s.c., a significant increase (more than fivefold, from 4.8 6 2.2 to 24.2 6 3.4) of EPCs (Sca-1 + VEGFR-2 + cells) was noticed at 0.5 hours postinjection. Peak mobilization (more than 12-fold increase, from 5.2 6 1.6 to 64.0 6 4.1) of EPCs occurred at 1 hour postinjection (Fig. 1A) . Dose-response analysis at 1 hour postinjection showed that a dose as low as 0.625 mg/kg AMD3100 could mobilize EPCs significantly compared with control (11.2 6 3.4 vs. 5.2 6 1.6, P , 0.05). Maximal mobilization of EPCs at 1 hour was noted with 2.5 to 10.0 mg/kg AMD3100 s.c. (Fig. 1B) .
Characterization of Spleen-Derived EPCs
Spleen-derived MNCs were cultured in endothelial cell selection medium for 4 days. Attached cells turned into spindle-shaped cells ( Fig. 2A) , and 88.7 6 4.8% of them showed uptake of ac-LDL and lectin binding, demonstrating endothelial cell characteristics (Fig. 2B ). These cells were characterized further by demonstrating the expression of the mouse stem-cell marker Sca-1 (54.0 6 4.2%) as well as the endothelial cell lineage antigen VEGFR-2 (62.9 6 3.5%) by flow cytometry (n = 8). 
AMD3100 Decreased EPC Numbers In Vitro
Spleen-derived MNCs were incubated with different concentration of AMD3100 for 24 hours. Counting double fluorescent staining positive cells revealed that incubation of spleen-derived MNCs with AMD3100 decreased the number of differentiated, adherent EPCs in a concentration-dependent manner, which became apparent at 5 ng/mL, with a peak at 50 ng/mL (Fig. 3A) . In time-course experiments performed with 50 ng/mL AMD3100, decrease of EPC number became apparent at 6 hours and reached the maximum at 24 hours (Fig.  3B) . As MNCs were treated with 100 ng/mL SDF-1a for 24 hours, the number of EPCs was increased obviously (100 ng/mL SDF-1a vs. control; 97.25 6 5.04 vs. 66.31 6 4.80, P , 0.001). Coexisted with 50 ng/mL AMD3100, 100 ng/mL SDF-1a could not increase the number of EPCs compared with the control (68.57 6 6.12 vs. 66.31 6 4.80, P . 0.05).
Effect of AMD3100 on EPC Proliferation
Data in MTT assay showed that AMD3100 inhibited the proliferative activity of spleen-derived EPCs in a concentrationdependent manner that got a statistic difference at 5 ng/mL and reached a maximum at 50 ng/mL (Fig. 4A) . When 50 ng/mL AMD3100 was used, EPC proliferative activity was decreased in a time-dependent manner, which became apparent at 6 hours and reached the maximum at 24 hours (Fig. 4B) . SDF1a 100 ng/mL improved EPC proliferation significantly (100 ng/mL SDF-1a vs. control; 0.8166 0.047 vs. 0.583 6 0.038, P , 0.001). The proliferation was markedly reduced when EPCs were incubated with 50 ng/mL AMD3100 and 100 ng/mL SDF-1a compared with the 100 ng/mL SDF-1 a-treated group (0.629 6 0.041 vs. 0.816 6 0.047, P , 0.001). However, various AMD3100 concentrations incubation did not change the proliferative activity of HPDE6 (Fig. 4A) .
Effect of AMD3100 on EPC Migration
In the present study, we investigated the effect of AMD3100 on the SDF-1a-mediated EPC migration. Data revealed that pretreatment of spleen-derived EPCs with 5 ng/mL AMD3100 significantly reduced cell migration in response to 100 ng/mL SDF-1a, and a maximal reduction was achieved with 50 ng/mL AMD3100 (Fig. 5A) . AMD3100 (50 ng/mL) also time-dependently decreased EPC migratory activity, which became apparent at 0.5 hours and reached the maximum at 2 hours (Fig. 5B ). In line with previous finding, the CXCR4-negative cell line HPDE6 did not migrate to SDF-1a, and pretreatment of HPDE6 with various AMD3100 concentrations did not change migratory cell activity (Fig. 5A) .
Effect of AMD3100 on EPC Adhesiveness
Effect of AMD3100 on EPC adhesiveness was evaluated in our present study. After being replated on fibronectin-coated dishes, EPCs pre-exposed to AMD3100 exhibited a significant decrease in the number of adherent cells. The decrease was in a concentration-dependent manner with a statistic difference achieved at 5 ng/mL and a maximal effect achieved at 50 ng/mL (Fig. 6A) . AMD3100 50 ng/mL also time-dependently decreased EPC adhesive activity, which became significant on a statistical level at 3 hours and reached the maximum at 12 hours (Fig. 6B) . Incubation of EPCs with 100 ng/mL SDF-1a distinctly increased the number of adherent cells 
Effect of AMD3100 on EPC Apoptosis
After incubation with AMD3100, EPC apoptosis was assessed by TUNEL method. A dose-dependent increase of apoptosis was noticed as EPCs were incubated with different concentration of AMD3100 for 48 hours. AMD3100 at a dose of 10 ng/mL could induce EPC apoptosis significantly, and a maximal effect was achieved at 50 ng/mL (Fig. 7A) . Incubation of EPCs with 50 ng/mL AMD3100 resulted in a time-dependent increase of EPC apoptosis, which became apparent at 6 hours and reached the maximum at 48 hours (Fig.  7B) . The efficiency of 50 ng/mL AMD3100 in inducing EPC apoptosis was inhibited markedly when coexisted with 100 ng/mL SDF-1a compared with the same AMD3100 concentration treated group (6.95 6 3.14% vs. 16.79 6 4.05%, P , 0.001). SDF-1a 100 ng/mL could also reduce spontaneous EPC apoptosis (100 ng/mL SDF-1a vs. control; 1.06 6 1.33% vs. 3.3 6 2.59%, P , 0.01). However, various AMD3100 concentrations incubation could not induce apoptosis of HPDE6 (Fig. 7A) .
SDF-1a Concentration in Cell Culture Supernatants
To assess the ability of spleen-derived EPCs to produce SDF-1, the concentration of SDF-1a in cell-culture supernatants was analyzed. Interestingly, a significant increase of SDF-1a concentration was noticed in cell-culture supernatants of different time span, compared with unused media samples.
It increased to more than 1 ng/mL in cell culture supernatants on days 4 to 7 and reduced gradually later (Fig. 8) .
DISCUSSION
As EPCs contribute to reendothelialization and neovascularization, increasing the number of these cells may be an attractive therapeutic tool. More recently, the interactions between SDF-1 and CXCR4 in hematopoietic progenitor cells (HPC) biology and mobilization have become an area of intense investigation. CXCR4 is normally found on HPC and SDF-1 is found on stromal cells and bone marrow endothelium. This receptor ligand interaction is important for HPC trafficking to the marrow and their retention there. AMD3100 is a bicyclam derivative that reversibly competes with and inhibits SDF-1 binding to CXCR4. 26, 27 Broxmeyer et al 28 demonstrated a 40-fold increase in circulating murine progenitor cells 1 hour after AMD3100 administration. Studies of AMD3100 in normal human subjects demonstrated that AMD3100 was, in fact, capable of mobilizing CD34 + cells from 2.6 to 40.4/mL at 9 hours after a single dose of 240 mg.
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When AMD3100 was administered after 4 to 5 days of G-CSF, further significant sustained increases of circulating CD34 + cells were observed in normal subjects within 6 hours from injection. 30 In studies of myeloma and lymphoma patients, a single dose of AMD3100 caused a statistically significant increase in CD34 + cells from a baseline of 2.6/mL reaching to 15.6/mL at 4 hours and 16.2/mL at 6 hours after injection. 31 Our present studies demonstrated for the first time that a single injection of AMD3100 could mobilize murine EPCs rapidly (1 hour), even in lower doses (0.625 mg/kg), which achieved a maximal effect at 2.5 to 10.0 mg/kg. Previous finding FIGURE 5. AMD3100 decreases EPC migration. A, AMD3100 decreased SDF-1a-induced EPC migration in a concentration-dependent manner, but pretreatment of HPDE6 with AMD3100 did not affect cells migratory activity. B, 50 ng/mL AMD3100 also time-dependently decreased EPC migratory activity; n = 6 experiments/group. b P , 0.01. showed that SDF-1 was mainly expressed in bone marrow and EPCs have a high-level expression of CXCR4. 15 So we conclude that SDF-1-CXCR4 axis is important for retention of EPCs in the murine marrow microenvironment and blocking the interactions between SDF-1 and CXCR4 with AMD3100 results in rapid and potent mobilization of EPCs into peripheral blood.
Reports indicated that SDF-1 could increase EPC number, 14 induce EPC migration, 15 and protect EPCs from apoptosis. 15 Given the expression of CXCR4 on EPCs 15 and the above described effects of SDF-1 on EPCs, we investigated the hypothesis that AMD3100, a selective antagonist of SDF-1 that binds to its receptor, CXCR4, might affect the functions of EPCs. Our in vitro results showed that AMD3100 decreased the number of differentiated, adherent EPCs in a concentrationtime dependent manner, and inhibited the proliferation, migration, and adhesiveness of EPCs in same manner. Additionally, AMD3100 induced EPC apoptosis in our study. Coexisting with SDF-1a, AMD3100 inhibited the favorable effects of SDF-1a on EPC functions. In contrast, AMD3100 did not affect the functions of CXCR4-negative cell line HPDE6. It suggests that AMD3100 impairs EPC functions by blocking the CXCR4 receptor of EPCs, and it was not a toxicity of AMD3100.
Recently, it was reported that SDF-1 can be synthesized by EPCs. 13 In the present study. SDF-1a concentration was found to be increased in EPC culture supernatants of different time spans, and it reached over 1 ng/mL in the cell-culture supernatants of days 4 to 7. It suggested that EPCs can produce high levels of SDF-1. SDF-1 is implicated in migration, proliferation, differentiation, and survival of many cell types including human and murine hematopoietic stem/progenitor cells. 14, 15, [32] [33] [34] [35] Combining with the upper result that AMD3100 impairs EPC functions by blocking EPC CXCR4 receptor, we conclude that EPCs have an autocrine/paracrine SDF-1 loop, and breaking this loop with AMD3100 can decrease the number of EPCs, inhibit the proliferation, migration and adhesiveness of EPCs, and induce EPC apoptosis. However, the fact that blocking CXCR4 or SDF-1 reduced but did not completely inhibit the biological functions of EPCs suggests that other factors and pathways than CXCR4/SDF-1 interactions are also involved in the regulation of these processes. 13 Given the close relationship between peripheral blood EPC number and cardiovascular diseases, and the treatment effects of EPC-mediated angiogenesis and reendothelialization in cardiovascular diseases, a rapid and efficient EPC mobilization with AMD3100 s.c. may play a crucial role in prevention and treatment of cardiovascular diseases, including improvement of neovascularization in ischemic tissues. But in vitro, AMD3100 inhibited some biological functions of EPCs in our present study. This was supported by recently published data that showed disturbance of CXCR4 signaling impair EPC functions. 36 SDF-1 expression in ischemic tissues has been demonstrated to induce EPC mobilization and enhance EPC recruitment at sites of neovascularization in ischemic tissues. In theory, injection of AMD3100 may disturb the effects of SDF-1 and play a deleterious role on neovascularization in ischemic tissues. Further studies are needed to elucidate the real effect of AMD3100 injection on neovascularization in ischemic tissues.
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